BPC-157: What the Preclinical Literature Actually Shows

BPC-157 is a chain of fifteen amino acids: glycine, glutamic acid, three prolines, glycine, lysine, proline, alanine, two aspartic acids, alanine, glycine, leucine and valine - written GEPPPGKPADDAGLV. It carries no non-standard residues, no cyclisation and no chemical modification, which makes it structurally unremarkable and cheap to synthesise.

What makes it interesting is where the sequence came from. It is a fragment of a larger protein called Body Protection Compound, which was isolated from human gastric juice. BPC-157 is therefore synthetic in the sense that it is manufactured rather than extracted, but the sequence itself is not a designed molecule - it is a naturally occurring one, excerpted.

That origin also explains its most-cited physical property. Most peptides are destroyed rapidly in gastric acid; a peptide that evolved in gastric juice is not. The literature reports stability in human gastric juice beyond 24 hours, which is why oral administration appears in the animal studies at all, where for most peptides it would be pointless.

For most of its history, BPC-157 was a compound with reported effects and no identified receptor. The 2017 work by Hsieh and colleagues changed that by tying it to VEGFR2 - vascular endothelial growth factor receptor 2, the principal receptor governing endothelial cell proliferation and new vessel formation.

Their finding was twofold: BPC-157 both activated VEGFR2 and increased its expression, with the signal propagating downstream through Akt and endothelial nitric oxide synthase. The nitric oxide arm connects to a separate and older strand of the BPC-157 literature, in which the peptide's effects are modulated by L-NAME and L-arginine - the standard pharmacological tools for blocking and supplying the nitric oxide pathway.

It is worth being precise about what this does and does not establish. It identifies a pathway through which an angiogenic effect could plausibly occur, in cells. It does not establish that this is the pathway responsible for the tissue-level outcomes reported in rodents, nor that either occurs in humans at any given exposure.

BPC-157 has a large literature and a small evidence base. Those are different things, and conflating them is the most common error made about this compound.

The volume is genuine - hundreds of indexed papers spanning tendon, ligament, muscle, gut, nerve and vascular models. But the great majority are rodent studies, many originate from a small number of closely associated research groups, and independent replication is thin. The 2025 systematic review by Vasireddi and colleagues applied formal inclusion criteria to the orthopaedic subset and found effectively no controlled human data to appraise.

There was one real attempt at clinical development. Under the code PL 14736, the Croatian pharmaceutical company Pliva took BPC-157 into early-phase trials for inflammatory bowel disease. That programme is documented in the literature and did not yield a published Phase 3 result. A compound that entered formal development and did not complete it is in a different evidential position than one that was never tested - and in a different position again from one that succeeded.

The gaps are as informative as the findings, and the 2025 narrative review by McGuire and colleagues is direct about them.

There is no published long-term toxicology in humans and no carcinogenicity data. That absence carries specific weight here rather than being a generic caveat: the best-supported mechanism for BPC-157 is pro-angiogenic, and promoting new blood vessel formation is not a neutral property in the presence of undetected malignancy. This is a theoretical concern rather than an observed harm, but it is the concern that follows directly from the mechanism the literature does support.

Human pharmacokinetics are similarly unpublished - absorption, distribution, half-life and clearance are not characterised in the indexed literature. Reviewers have also repeatedly noted that material circulating outside controlled channels is of unverified identity and purity, which makes reported experiences difficult to attribute to the compound at all.